Hansoh BioMedical R&D Company

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

12 drugs in development

Phase 35

Phase 28

Phase 17

Preclinical1

By Therapeutic Area

top 4

Oncology

964%

Immunology

214%

Nephrology

17%

Dermatology

17%

R&D Momentum

68/100

Pipeline Velocity

34/100

Trial Completion Rate

75/100

Pipeline Concentration

45/100

Pipeline Freshness

82/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Oct 31, 2026

Active, not recruiting

A Phase Ib Clinical Study on the Efficacy, Safety, Tolerability, and Pharmacokinetics of HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Oct 24, 2026

Recruiting

A Multicenter, Randomized, Open-Label, Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Earlier

Oct 21, 2026TrialAn Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of HS-20137, an Anti-IL-23 Monoclonal Antibody, in Participants With Moderate-to-severe Plaque Psoriasis

Oct 20, 2026TrialA Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20093 for Injection Versus Gemcitabine in Combination With Docetaxel in the Treatment of Osteosarcoma After Previous Second-line Treatment Failure (ARTEMIS-011)

Oct 17, 2026TrialARTEMIS-008：A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Sep 23, 2026TrialA Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20197 in Participants With Advanced Solid Tumors

Sep 17, 2026TrialAn Open-label, Multicentre, Randomized, Controlled Phase III Clinical Trial Comparing HS-20089 Plus Bevacizumab Versus Investigator's Choice of Platinum-based Chemotherapy Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Aug 21, 2026TrialA Phase I Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of HS-20117-2 Injection in Patients With Advanced Solid Tumors

2 more events

Jul 7, 2026TrialA PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS

Mar 31, 2026TrialA Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Details